Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$506.34 USD

506.34
1,041,901

+2.50 (0.50%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $506.75 +0.41 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Retain STERIS Stock in Your Portfolio for Now

by Zacks Equity Research

STE's strong prospects in the healthcare business arm bode well for investors.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

by Zacks Equity Research

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

by Zacks Equity Research

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

by Zacks Equity Research

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

by Zacks Equity Research

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

by Zacks Equity Research

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

by Zacks Equity Research

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

by Zacks Equity Research

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

by Zacks Equity Research

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

Intuitive Surgical, Inc. (ISRG) Stock Moves 1.03%: What You Should Know

by Zacks Equity Research

The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $487.17, representing a +1.03% change from its previous close.

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

by Zacks Equity Research

PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

by Zacks Equity Research

NEOG faces intense competition, which could affect the marketability and profitability of its products.

ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition

by Zacks Equity Research

Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.

Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Quest Diagnostics Expands in North America With New Acquisition

by Zacks Equity Research

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.

Reasons to Retain QIAGEN Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.

Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update

by Zacks Equity Research

The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access

Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.

SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

by Zacks Equity Research

SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.

Intuitive Surgical, Inc. (ISRG) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $486.55, signifying a -0.79% move from its prior day's close.

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

by Zacks Equity Research

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks

by Zacks Equity Research

With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.

Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

by Zacks Equity Research

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch

by Zacks Equity Research

Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.